VIROMARKERS is a public private partnership aimng at the development of biomarkers that would revolutionise the care of people living with HIV and hepatitis D, as well as stem cell transplant patients at risk of cytomegalovirus (CMV) infection or reactivation.

VIROMARKERS will evaluate virus related biomarkers including both biomarkers of response to antiviral treatment (for HIV and HDV) and virome features (CMV and TTV) as indicators of disease progression in immunosuppressed people.

The project includes all the preliminary lab activities to set up or refine investigational methods to measure the biomarker(s) considered. Validation or demonstration of the technologies required to measure the candidate biomarkers is an integral part of the project objectives. 

Assay setup within VIROMARKERS will generate the experimental data necessary to move prototype methods through the regulatory steps necessary to reach clinical application.

The involvement of pharma and diagnostic companies together with care and research institutions, community representatives and a European regulatory body will bring about innovative results into the clinics!